
In the MOSCA-FRAIL trial, frail older adults (≥70 years) with NSTEMI were randomized to invasive or conservative strategies. At a 3-year follow-up, invasive management did not reduce reinfarction risk. Mortality was higher initially in the invasive group but decreased over time. Given the high mortality associated with frailty, invasive treatment had limited impact on reinfarction rates, suggesting that further research is needed.
Like
Save
Share